Clinical trials · North Carolina
Recurrent Endometrial Carcinoma clinical trials in North Carolina
We’re tracking 11 recruiting recurrent endometrial carcinoma studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Cary, North CarolinaAges 18 years+ - NCT07198074RecruitingPhase 3
Testing Avastin added to chemo plus Keytruda for certain endometrial cancer
This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Asheboro, North CarolinaAges Any age - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Durham, North CarolinaAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Charlotte, North CarolinaAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Chapel Hill, North CarolinaAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Durham, North CarolinaAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Pinehurst, North CarolinaAges 18 years+ - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Durham, North CarolinaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Charlotte, North CarolinaAges 18 years+
Recurrent Endometrial Carcinoma trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting recurrent endometrial carcinoma studies listed above.
- Duke University Health System · 4 studies
- Duke University Medical Center · 4 studies
- UNC Lineberger Comprehensive Cancer Center · 3 studies
- Atrium Health Wake Forest Baptist Hayworth Cancer Center · 2 studies
- Duke Cancer Institute · 2 studies
- Southeastern Medical Oncology Center · 2 studies
- Southeastern Medical Oncology Center-Clinton · 2 studies
- Southeastern Medical Oncology Center-Jacksonville · 2 studies
What taking part in a recurrent endometrial carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Endometrial Carcinoma trials in other states
Common questions
- Are there recurrent endometrial carcinoma clinical trials in North Carolina?
- Yes. We're currently tracking 11 recruiting recurrent endometrial carcinoma studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent endometrial carcinoma study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent endometrial carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent endometrial carcinoma studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.